Skip to content
The Policy VaultThe Policy Vault

Imbruvica (ibrutinib) — Medica

Chronic Lymphocytic Leukemia (CLL)

Initial criteria

  • Patient is age ≥ 18 years

Reauthorization criteria

  • Patient continues to meet initial criteria

Approval duration

1 year